Scientists hail breakthrough in fight against deadly Ebola virus
Scientists have developed a new kind of "antisense" drug that has produced promising results in laboratory trials involving the Ebola and Marburg viruses, two of the most lethal known. The drug works by blocking the critical genes that the viruses use to replicate quickly inside the body to give patients valuable time to mount their own immune defence against the viral haemorrhagic fevers.
Tests on laboratory animals have shown that the antisense drugs are effective at fending off Ebola and Marburg, which cause rapid and intense fever and internal bleeding fatal in about 90 per cent of cases.
There are at present no effective treatments or vaccines against either of the viruses, which are highly infectious and have caused particular concern because of the possibility of them being used in biowarfare or as a terrorist weapon. The antisense drugs are composed of short strands of nucleic acids which form a sequence that is complementary or opposite to the nucleic acid sequence found in the genes of the viruses. They work by binding to the viral genes and blocking their action, giving time for the immune defences of the patients to launch an attack on the invading viruses, the scientists said.
The researchers, from the US Army Medical Research Institute of Infectious Diseases (Usamriid), report in the journal Nature Medicine that an antisense drug called AVI-6002 resulted in a survival rate of better than 90 per cent in laboratory mice and guinea pigs exposed to the Ebola virus. When the scientists tested the drug on laboratory monkeys, three out of five survived.
A similar antisense drug, called AVI-6003, proved even more successful against the Marburg virus, with every one of the treated monkeys surviving a viral attack, the study showed.
Ebola and Marburg are considered so dangerous that the research had to be done in special laboratories with the highest security classification, known as biosafety level 4, where the scientists had to wear space-suits and breathe filtered air to protect them as they did their experiments.
The scientists, led by Travis Warren of the Usamriid, believe the results are good enough to warrant clinical trials in humans and the US Food and Drug Administration has given permission to proceed.
The scientists said they have developed "human-grade" antisense drugs that could be used on people after an emergency in 2004, when a laboratory worker in the Usamriid was accidentally pricked in the thumb with a needle while treating Ebola-infected mice. The female worker was isolated, but found to be uninfected, so the human-grade antisense drug was not used on her. But the facility has worked with biotechnology company AVI BioPharma to develop antisense drugs to be used in human clinical trials.
- 1 Caitlyn Jenner car crash: Driver who died in collision sued by surviving passengers for $18.5m
- 3 Watch the Supermoon live: How to see the brightest Moon of the year tonight
- 4 Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
Caitlyn Jenner car crash: Driver who died in collision sued by surviving passengers for $18.5m
Celebrity Big Brother 2015: Tila Tequila kicked off show after 'describing Hitler as a good man'
Watch the Supermoon live: How to see the brightest Moon of the year tonight
Hulk Hogan wants to be Donald Trump's running mate in the US Presidential election
Blood Moon and Supermoon: September to bring brightest – and dimmest – full Moon of the year on same night
Climate change: 2015 will be the hottest year on record 'by a mile', experts say
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith 'should resign over disability benefit death figures', says Jeremy Corbyn
Stock up on canned food for stock market crash, warns former Gordon Brown adviser
Labour leadership: Jeremy Corbyn voters most likely to believe 'world is controlled by a secretive elite'
£18000 - £30000 per annum: Recruitment Genius: A Sales Executive or Senior Sal...
£40000 - £55000 per annum: Recruitment Genius: This is an exciting opportunity...
£22000 per annum: Recruitment Genius: This industry leading company produces h...
£20000 - £40000 per annum: Recruitment Genius: This IT provider for the educat...